Anti-Thymocyte Globulin Prophylaxis Induces a Decrease in Naive Th Cells to Inhibit the Onset of Chronic Graft-versus-Host Disease: Results from the Canadian Bone Marrow Transplant Group (CBMTG) 0801 Study
Leonie Naeije, Amina Kariminia, Sayeh Abdossamadi, Shima Azadpour, Peter Subrt, Boris Kuzeljevic, Michael A Irvine, Irwin Walker, Kirk R Schultz, Leonie Naeije, Amina Kariminia, Sayeh Abdossamadi, Shima Azadpour, Peter Subrt, Boris Kuzeljevic, Michael A Irvine, Irwin Walker, Kirk R Schultz
Abstract
Anti-thymocyte globulin (ATG) is an established approach to decrease chronic GVHD (cGVHD), yet the exact mechanism is uncertain. To better understand the mechanism of action of ATG in preventing cGVHD, we evaluated the day 100 immune reconstitution of known cGVHD cellular biomarkers using patients from the randomized Canadian Bone Marrow Transplant Group (CBMTG) 0801 trial, which demonstrated a significant impact of ATG on cGVHD. In a separate companion biology study, we evaluated the impact of ATG prophylaxis on cGVHD cellular markers at day 100 in 40 CBMTG 0801 patients. Analysis focused on previously identified cGVHD cellular biomarkers, including naive helper T (Th) cells, recent thymic emigrant (RTE) Th cells, CD21low B cells, CD56bright NKreg cells, and Treg cells ST2, osteopontin, soluble B-cell activating factor (sBAFF), Interleukin-2 receptor alpha (sCD25), T-cell immunoglobulin and mucin domain-3 (TIM-3), matrix metallopeptidase 3, ICAM-1, C-X-C motif chemokine 10 (CXCL10), and soluble aminopeptidase N. The ATG-treated group had a >10-fold decrease in both RTE naive Th and naive Th cells (P < .0001) and a 10-fold increase in CD56bright NKreg cells (P < .0001). Treg cells, conventional Th cells, CD21low B cells, and all plasma markers were not affected. In the populations most affected by ATG, changes in naive Th cells were associated with the later development of cGVHD. This analysis suggests that ATG primarily impacts on cGVHD through suppression of naive Th cell expansion after transplantation. These associations need to be validated in additional studies.
Trial registration: ClinicalTrials.gov NCT01217723.
Keywords: ATG; Biomarkers; Development cGVHD; Hematopoietic stem cell transplantation; Naive Th cells.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Source: PubMed
Upcoming Clinical Trials
-
Artvin Coruh UniversityNot yet recruitingCharcot Marie Tooth Disease (CMT)Turkey (Türkiye)
-
University of Management and Technology LahoreNot yet recruitingKnee OsteoarthritisPakistan
-
Regeneron PharmaceuticalsRecruiting
-
Kirsehir Ahi Evran UniversitesiNot yet recruitingChild Abuse | Nursing Education | Child Neglect | Child Sexual Abuse
-
Lokman Hekim UniversityNot yet recruitingNursing EducationTurkey (Türkiye)
-
Imagion Biosystems, Inc.RecruitingHER2-positive Breast CancerUnited States
-
Ankara City Hospital BilkentRecruitingFear of Childbirth | Ceserean Section | LABOR PAİNTurkey (Türkiye)
-
Örebro University, SwedenRecruiting
-
Oorja Bio, Inc.Recruiting
-
Cairo UniversityNot yet recruitingCervical Radiculopathy at C6 Nerve RootEgypt
-
Indiana UniversityRecruitingPregnancy Prevention | Male Contraception | Contraceptive Device | Prevention of Semen Exposure During IntercourseUnited States
-
Tianjin Medical University Cancer Institute and...Not yet recruitingMantle Cell Lymphoma (MCL) | Relapsed/Refractory Mantle Cell Lymphoma (MCL)China